Biogen (BIIB) Shares Active on M&A Chatter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- AXT-Tongmei signs 3-year wafer supply deal with Coherent
Biogen (BIIB) Could Be Worth $375-475/Share in a Takeover - RBC Capital's Yee
August 2, 2016 3:41 PM EDTBiogen (NASDAQ: BIIB) could be worth $375-$475/share in a takeover RBC Capital's Michael Yee said following reports from the WSJ the company has attracted takeover... More
Biogen (BIIB) Peers on Watch Amid M&A Chatter (AMGN) (GILD)
August 2, 2016 2:52 PM EDTBiogen (NASDAQ: BIIB) peers are on watch amid today's M&A chatter. Names include: Celgene (NASDAQ: CELG), Gilead Sciences (NASDAQ: GILD), and Amgen (NASDAQ: AMGN), among others.
... MoreBiogen (BIIB) Draws Takeover Interest from Allergan (AGN), Merck (MRK) - DJ
August 2, 2016 2:43 PM EDT(Updated - August 2, 2016 2:49 PM EDT)
Biogen (Nasdaq: BIIB) attracted takeover interest from Allergan (NYSE: AGN) and Merck (NYSE: MRK), according to Dow Jones, citing sources. The two companies reportedly... More
Biogen (BIIB) triggers LUDP trading pause
August 2, 2016 2:43 PM EDTBiogen (NASDAQ: BIIB) triggers LUDP trading pause.
... MoreBiogen (BIIB) PT Raised to $367 at Leerink Partners
August 1, 2016 3:18 PM EDTLeerink Partners analyst Geoffrey Porges raised his price target on Biogen (NASDAQ: BIIB) to $367.00 (from $360.00) but maintained an Market Perform following positive nusinersen data.
Porges commend, "This morning Biogen and Ionis (MP) announced that ENDEAR, a phase 3 study of nusinersen in the treatment of infant-onset (Type I) spinal muscular atrophy (SMA), met its primary pre-specified endpoints following an interim analysis. In a conference call following the... More
